COMPARISON OF THE PHARMACOKINETICS AND PHARMACODYNAMICS OF ORAL DOSES OF PERINDOPRIL IN NORMOTENSIVE CHINESE AND CAUCASIAN VOLUNTEERS

被引:0
|
作者
ANDERSON, PJ
CRITCHLEY, JAJH
TOMLINSON, B
RESPLANDY, G
机构
[1] CHINESE UNIV HONG KONG,PRINCE WALES HOSP,DEPT CLIN PHARMACOL,SHA TIN,HONG KONG
[2] INST RECH INT SERVIER,F-92400 COURBEVOIE,FRANCE
关键词
PERINDOPRIL; PERINDOPRILAT; PHARMACOKINETICS; CHINESE; CAUCASIANS;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 The pharmacokinetics of perindopril and perindoprilat and the hormonal and haemodynamic responses following a single oral dose were studied in 12 Chinese and 10 Caucasian healthy, normotensive volunteers on two occasions. Perindopril was given on the first occasion as a 4 mg dose and then after at least 10 days as a weight-adjusted dose of 4 mg/70 kg. Plasma was sampled for assay of perindopril, perindoprilat, plasma renin activity (PRA), aldosterone, angiotensin I (AI) and ACE activity. Urine was collected for perindopril and perindoprilat assay. A radioimmunoassay technique was used to measure the prodrug and its active metabolite. 2 The time to maximum concentration (t(max)) for perindopril was shorter for the Chinese group after the 4 mg dose (median 0.5, range 0.5-1.5 h vs median 1.0, 0.5-1.5 h P < 0.05) and also tended to be shorter after the weight-adjusted dose (median 0.5, range 0.5-1.0 h vs median 1.0, range 0.5-3.0 h). C-max and AUC tended to be higher after the 4 mg dose in the Chinese group who had a lower body weight than the Caucasians. 3 The t(max) of perindoprilat tended to be shorter for both doses and there was a tendency towards a higher C-max after the 4 mg dose in the Chinese group but there was no statistically significant difference between the two groups. 4 There were no differences in the levels of PRA, plasma AI, plasma aldosterone or the degree of ACE-inhibition for either dose in the two ethnic groups. 5 Blood pressure was measured at intervals up to 24 h post-dose in both the supine and standing positions. Perindopril reduced blood pressure acutely with respect to the pre-dose level with good tolerability in both groups. 6 The pharmacokinetics of perindopril are essentially the same in Chinese and Caucasians although absorption of the prodrug and conversion to the active metabolite appeared to be more rapid in the Chinese group. However, there were no differences in its hormonal or haemodynamic effects and no alteration of the standard dose of 4 mg appears to be necessary for Chinese subjects.
引用
收藏
页码:361 / 368
页数:8
相关论文
共 50 条
  • [41] PXR polymorphisms and their impact on pharmacokinetics/pharmacodynamics of repaglinide in healthy Chinese volunteers
    Qing-qing Du
    Zhi-jun Wang
    Lin He
    Xue-hua Jiang
    Ling Wang
    European Journal of Clinical Pharmacology, 2013, 69 : 1917 - 1925
  • [42] Pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects after oral administration of dabigatran etexilate
    Haertter, Sebastian
    Yamamura, Norio
    Stangier, Joachim
    Reilly, Paul A.
    Clemens, Andreas
    THROMBOSIS AND HAEMOSTASIS, 2012, 107 (02) : 260 - 269
  • [43] THE EFFECTS OF AGE ON THE PHARMACOKINETICS AND PHARMACODYNAMICS OF SINGLE ORAL DOSES OF BENAZEPRIL AND ENALAPRIL
    MACDONALD, NJ
    SIOUFI, A
    HOWIE, CA
    WADE, JR
    ELLIOTT, HL
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 36 (03) : 205 - 209
  • [44] Pharmacokinetics and pharmacodynamics of single oral doses of albuterol and its enantiomers in humans
    Boulton, DW
    Fawcett, JP
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 62 (02) : 138 - 144
  • [45] Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban - an oral, direct factor Xa inhibitor - in elderly Chinese subjects
    Jiang, Ji
    Hu, Yufang
    Zhang, Jianyan
    Yang, Jueling
    Mueck, Wolfgang
    Kubitza, Dagmar
    Bauer, Richard J.
    Meng, Ling
    Hu, Pei
    THROMBOSIS AND HAEMOSTASIS, 2010, 103 (01) : 234 - 241
  • [46] Comparison of Pharmacokinetics of Aprepitant in Healthy Chinese and Caucasian Subjects
    Yang, Meng-Jie
    Xu, Hong-Rong
    Li, Hui
    Chen, Wei-Li
    Yuan, Fei
    Li, Xue-Ning
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2020, 14 : 1219 - 1226
  • [47] PHARMACODYNAMICS AND PHARMACOKINETICS OF SINGLE DOSES OF KETANSERIN AND PROPRANOLOL ALONE AND IN COMBINATION IN HEALTHY-VOLUNTEERS
    WILLIAMS, FM
    LEESER, JE
    RAWLINS, MD
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 22 (03) : 301 - 308
  • [48] Safety, pharmacokinetics, and pharmacodynamics of ascending multiple oral doses of a new protease activated receptor-1 inhibitor in healthy volunteers
    Marion, A.
    Reyes, J.
    Chen, H.
    Wittek, A.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (09): : 1085 - 1085
  • [49] The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of CH4987655 in Healthy Volunteers: Target Suppression Using a Biomarker
    Lee, Lucy
    Niu, Huifeng
    Rueger, Ruediger
    Igawa, Yuriko
    Deutsch, Jonathan
    Ishii, Nobuya
    Mu, Song
    Sakamoto, Yuuichiro
    Busse-Reid, Rachel
    Gimmi, Claude
    Goelzer, Petra
    De Schepper, Stefanie
    Yoshimura, Yashushi
    Barrett, Joanne
    Ishikawa, Yuji
    Weissgerber, Georges
    Peck, Richard
    CLINICAL CANCER RESEARCH, 2009, 15 (23) : 7368 - 7374
  • [50] Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers
    Huettner, S.
    Graefe-Mody, E. U.
    Withopf, B.
    Ring, A.
    Dugi, K. A.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (10): : 1171 - 1178